Examkin

Question

Difficulty: HardPharmacologic Interventions

A 6868-year-old man presents to the clinic for follow-up of newly diagnosed atrial fibrillation. Three weeks ago, he presented to the emergency department with palpitations and was found to be in paroxysmal non-valvular atrial fibrillation. An echocardiogram demonstrated a structurally normal heart with a left ventricular ejection fraction of 60%60\%. He spontaneously converted to normal sinus rhythm and is currently asymptomatic. His past medical history is significant for hypertension, type 22 diabetes mellitus, and a seizure disorder secondary to a remote traumatic brain injury. His medications include lisinopril, metformin, and phenytoin. He has been seizure-free for the past 44 years on his current dose of phenytoin. Vital signs are within normal limits. Recent laboratory studies, including a basic metabolic panel and complete blood count, are unremarkable. Liver function tests reveal a mildly elevated total bilirubin of 1.41.4 mg/dL (normal: 0.10.1-1.21.2 mg/dL) with normal transaminases and alkaline phosphatase. His CHA 2_2 DS 2_2-VASc score is calculated to be 33. Which of the following is the most appropriate pharmacologic intervention for stroke prevention in this patient?

  1. A
    Initiate apixaban therapy
  2. Initiate warfarin therapyAnswer
  3. C
    Initiate dabigatran therapy
  4. D
    Initiate rivaroxaban therapy and adjust the dosage to maintain an International Normalized Ratio (INR) between 2.02.0 and 3.03.0
  5. E
    Delay antithrombotic therapy until the mild hyperbilirubinemia resolves

Answer

The most appropriate pharmacologic intervention is to initiate warfarin therapy.
This patient requires oral anticoagulation for stroke prevention due to a CHA2DS2-VASc score of 3. However, he is well-controlled on phenytoin, a potent inducer of both the cytochrome P450 system (particularly CYP3A4) and P-glycoprotein (P-gp). Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran are substrates for these metabolic and efflux pathways. Co-administration of DOACs with potent inducers results in drastically reduced plasma concentrations of the anticoagulant, placing the patient at high risk for ischemic stroke. Furthermore, because DOACs lack widely available, standardized laboratory assays for routine therapeutic monitoring, their dosages cannot be safely titrated to overcome the induction effect. In contrast, while warfarin metabolism is also affected by hepatic induction, its therapeutic biologic effect is directly measurable via the International Normalized Ratio (INR). Therefore, a clinician can safely initiate warfarin and empirically titrate the dosage upward until the target therapeutic INR (2.0 to 3.0) is achieved, ensuring adequate stroke prevention.

Step-by-Step Solution

1
Calculate the stroke risk and determine the indication for therapy.
The patient has a CHA2DS2-VASc score of 3, providing a strong indication for oral anticoagulation for stroke prevention.
Current clinical guidelines mandate oral anticoagulation for men with a score of 2 or higher.
2
Evaluate current medications for potential pharmacokinetic interactions.
The patient takes phenytoin, which is a potent inducer of hepatic cytochrome P450 enzymes (specifically CYP3A4) and the efflux transporter P-glycoprotein (P-gp).
Recognizing potent inducers or inhibitors is critical before prescribing new long-term pharmacotherapy.
3
Assess the metabolism and monitoring parameters of available oral anticoagulants.
Direct oral anticoagulants (DOACs) are substrates of CYP3A4 and P-gp, and lack standard laboratory tests for routine titration. Warfarin is metabolized hepatically but can be monitored via the INR.
DOACs will have unpredictably low and subtherapeutic plasma levels when given with phenytoin, increasing the risk of ischemic stroke.
4
Select the safest and most effective anticoagulant regimen.
Warfarin is selected because the dose can be empirically titrated up based on INR measurements to ensure therapeutic anticoagulation despite the presence of the enzyme inducer.
Direct monitoring of the biologic effect (INR) bypasses the pharmacokinetic unpredictability caused by the enzyme inducer.

Key Concept

Direct oral anticoagulants (DOACs) are contraindicated or strongly cautioned in patients taking potent CYP3A4 or P-glycoprotein inducers (such as phenytoin or carbamazepine) because induction significantly reduces DOAC levels and risks therapeutic failure. Warfarin is preferred because its dose can be empirically titrated using the International Normalized Ratio (INR).
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic